Greenway Greenhouse Cannabis Corp. (GWAY) AI Stock Analysis

• Market Cap: C$21.26M
• Dividend Yield: N/A
• Average Volume (3M): 19.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: 19.66%
• EPS Growth: 84.34%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 132,844,530
• 10 Day Avg. Volume: 16,837
• 30 Day Avg. Volume: 19,312
• PEG Ratio: 0.22
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 17.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.16 ▼(-4.71% Downside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is weighed down primarily by weak financial quality (ongoing net losses, high leverage, and negative/volatile cash flow) despite some improvement in operating profitability. Technicals also remain bearish (negative MACD, RSI below 50, and price below the 200-day average). Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield.

Positive Factors

Improving operating profitability

The company has moved to positive EBIT/EBITDA with a materially stronger gross-profit profile in the trailing twelve months. Sustained operating profitability improvement supports reinvestment, reduces reliance on external funding, and is a durable step toward lasting break-even and cash generation if maintained.

Solid revenue growth trend

Consistent top-line expansion (reported RevenueGrowth) points to improving market traction and demand for its product. Durable revenue growth helps absorb fixed greenhouse costs, supports margin recovery, and provides a base for scaling operations and negotiating longer-term wholesale or provincial supply contracts.

Greenhouse cultivation specialization

A greenhouse cultivation model offers structural advantages: lower per-unit energy costs than indoor grows, scalable footprint, and stability in regulated wholesale supply chains. Specialization in greenhouse production supports predictable yields and positions the firm to serve provincial and B2B customers long term.

Negative Factors

Elevated leverage

Materially higher debt-to-equity increases financial risk and constrains strategic flexibility. Elevated leverage raises interest obligations and refinancing risk, which can magnify earnings volatility and impair the company's ability to invest in capacity or navigate weaker demand without diluting equity or cutting growth.

Negative and volatile cash flow

Negative and inconsistent operating and free cash flow imply the business frequently relies on external financing. Persistent cash burn undermines liquidity, raises the probability of future dilutive raises or higher-cost debt, and weakens the company's ability to sustain capex or weather cyclical softness in the cannabis market.

Ongoing net losses

Despite operating improvements, the company remains slightly unprofitable with a multi-year pattern of losses. Continued net losses erode retained earnings and constrain return on equity, making it harder to attract stable capital and signaling that the turnaround has durability risk until consistent net profitability is achieved.

Greenway Greenhouse Cannabis Corp. Business Overview & Revenue Model

Company Description

Greenway Greenhouse Cannabis Corporation engages in the cultivation, processing, and selling of dried cannabis flower and kief. The company was incorporated in 2018 and is based in Kingsville, Canada. Greenway Greenhouse Cannabis Corporation is a subsidiary of Sunrite Greenhouses Ltd.

How the Company Makes Money

Greenway Greenhouse Cannabis Corp. generates revenue primarily through the sale of its cannabis products to various markets, including medical dispensaries and recreational retailers. The company utilizes its state-of-the-art greenhouse facilities to produce cannabis efficiently and sustainably, reducing costs and enhancing product quality. Revenue streams include the sale of dried cannabis flowers, oils, and other derivative products. Key partnerships with distributors and retailers help expand the company's reach and market presence, contributing significantly to its earnings. Additionally, Greenway may engage in strategic collaborations or white-label agreements to further diversify its revenue sources.

Greenway Greenhouse Cannabis Corp. Financial Statement Overview

Summary

Operating performance improved in the TTM period (stronger gross profit and positive EBIT/EBITDA), but overall fundamentals remain weak due to bottom-line losses, elevated leverage (debt-to-equity ~1.58), and negative/volatile operating and free cash flow.

Income Statement

TTM (Trailing-Twelve-Months) revenue grew ~7.9% and profitability improved materially versus prior annual periods, with a much stronger gross profit profile and positive EBIT/EBITDA. However, the company is still slightly unprofitable at the bottom line (negative net margin), and the longer-term history shows several years of sizeable losses and weak margins, highlighting that the turnaround is still in progress and not yet fully proven.

Balance Sheet

Leverage remains a key constraint: total debt is high relative to equity (debt-to-equity ~1.58 in TTM (Trailing-Twelve-Months)), and returns on equity are negative, reflecting ongoing net losses. While equity is positive, the balance sheet has trended toward higher leverage versus earlier years (when debt-to-equity was closer to ~0.93–0.99), which increases financial risk if operating performance softens.

Cash Flow

Cash generation weakened in TTM (Trailing-Twelve-Months), with operating cash flow and free cash flow both negative, reversing the prior annual period where both were positive. The pattern over multiple years is volatile with frequent cash burn, implying execution risk and potential reliance on financing until cash flow becomes consistently positive.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	9.13M	8.95M	5.23M	5.62M	1.98M	0.00
Gross Profit	3.53M	1.68M	-335.38K	741.99K	844.02K	487.88K
EBITDA	2.76M	972.53K	-2.21M	-632.92K	-1.36M	-727.12K
Net Income	-213.13K	-2.06M	-4.72M	-2.61M	-2.92M	-1.23M
Balance Sheet
Total Assets	32.63M	32.26M	33.09M	35.30M	35.63M	25.11M
Cash, Cash Equivalents and Short-Term Investments	1.18M	3.14M	1.53M	3.64M	7.48M	3.46M
Total Debt	15.63M	15.79M	16.02M	13.96M	16.67M	13.85M
Total Liabilities	22.81M	22.21M	21.17M	20.36M	18.77M	14.85M
Stockholders Equity	9.82M	10.05M	11.92M	14.95M	16.86M	10.26M
Cash Flow
Free Cash Flow	-975.90K	1.61M	-4.96M	-4.38M	-4.10M	-5.95M
Operating Cash Flow	-779.77K	1.81M	-2.05M	2.23M	-1.97M	-592.08K
Investing Cash Flow	-196.13K	-194.37K	-2.92M	428.31K	-2.12M	-5.36M
Financing Cash Flow	0.00	0.00	2.85M	-6.49M	8.12M	7.97M

Greenway Greenhouse Cannabis Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GWAY, the sentiment is Negative. The current price of 0.17 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.16, and below the 200-day MA of 0.19, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.01 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GWAY.

Greenway Greenhouse Cannabis Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROMJ	55 Neutral	C$34.26M	3.70	7.78%	―	28.55%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVCN	46 Neutral	C$21.99M	-5.08	-68.32%	―	2.41%	74.61%
LABS	45 Neutral	C$27.35M	-3.68	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$10.76M	5.19	―	―	15.64%	58.47%
GWAY	41 Neutral	C$21.26M	-44.16	-2.15%	―	19.66%	84.34%
AYR.A	40 Neutral	C$18.10M	-0.08	―	―	0.63%	-31.86%

Greenway Greenhouse Cannabis Corp. Corporate Events

Greenway Lifts Revenue, Margins and Cash Efficiency in Q3 Results

Greenway Greenhouse Cannabis Corp. reported a 40% year-over-year increase in third-quarter net cannabis revenue to $2.35 million, alongside higher gross profit and an improved gross margin of 29%. The company also reduced its cash cost per gram sold to $0.92, generated positive operating income for a fourth consecutive quarter, and posted its fifth straight quarter of positive adjusted EBITDA.

Management highlighted a strong liquidity position, with more than $4.5 million combined cash and finished goods inventory supporting anticipated demand and ongoing scaling efforts. Greenway also issued 402,549 common shares to an external consultant as partial payment for corporate-finance advisory services, underscoring its use of equity-based compensation while it focuses on efficient production, yield optimization, and enhancing its product mix to sustain momentum.

The most recent analyst rating on (TSE:GWAY) stock is a Hold with a C$0.15 price target. To see the full list of analyst forecasts on Greenway Greenhouse Cannabis Corp. stock, see the TSE:GWAY Stock Forecast page.

Greenway Leverages Efficiency Gains and International Expansion to Accelerate Next Growth Phase

In its 2025 year-in-review, Greenway highlighted a year of disciplined execution marked by improved cultivation efficiency, stronger yields and tighter cost controls, which management views as a durable step-change underpinning its profitability strategy. The company advanced its international wholesale program with product now reaching multiple European jurisdictions and Australia, and it signed a strategic supply agreement with 4C Labs to serve the U.K. medical cannabis market, while delivering a 20% increase in annual revenue and a more than 40% rise in average selling price per gram. With additional cultivation capacity already built out that can lift production by over 75% without significant new capital spending, Greenway plans to ramp output in a measured, demand-driven manner, aiming to leverage growing international sales channels to drive higher volumes, revenue growth and operating leverage despite ongoing volatility in the Canadian cannabis sector.

The most recent analyst rating on (TSE:GWAY) stock is a Hold with a C$0.18 price target. To see the full list of analyst forecasts on Greenway Greenhouse Cannabis Corp. stock, see the TSE:GWAY Stock Forecast page.